Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies

NCT06880744 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06880744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06880744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 17, 2025
Completion date
August 31, 2027
Enrollment
573 (actual)
Sites
270

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis